OP-ED: Bias and Dysfunction in Cannabis Regulation at CBC
2026 cannabis regulatory dysfunction is creating challenges for patient access to quality cannabis medicines. Regulatory instability impacts product testing and licensing consistency. Clinicians face uncertainty recommending cannabis therapeutically amid…
Rescheduling Cannabis Under the Controlled Substances Act | Regulatory Review
Rescheduling cannabis regulatory impact under the Controlled Substances Act could transform research and clinical practice. Lower scheduling may enable more rigorous trials and standardized product development. This shift is crucial for advancing…
White House Schedules Cannabis Enforcement Meeting (Newsletter: March 27, 2026)
The federal cannabis enforcement policy is under review following the White House's scheduled meeting in March 2026. This policy directly affects patient access to medical cannabis and clinical practice guidelines. Healthcare providers should stay…
Aengus Bridgman on How Algorithms Perpetuate Disinformation in Cannabis Medicine
Algorithmic amplification cannabis misinformation significantly impacts patient safety and clinical decision-making. Understanding these dynamics helps clinicians educate patients effectively. This focus on cannabis misinformation algorithms is crucial…
Innovative Industrial Properties: Undervalued Amid Cannabis Rescheduling Milestone
The cannabis rescheduling milestone marks a pivotal change in federal law, impacting medical cannabis research and clinical practice. This shift to Schedule III could accelerate pharmaceutical development and alter regulatory frameworks. Understanding…
Medicinal Cannabis Prescription Before Psychiatric Admission: Audit Results
This study investigates medicinal cannabis psychiatric inpatient use through a retrospective observational audit. It highlights prescription patterns and safety concerns in psychiatric populations. The findings provide important baseline data for…
Congressman Demands DOJ Update on Marijuana Rescheduling
The marijuana rescheduling update remains pending as the DOJ has yet to respond three months after the executive order. This delay impacts federal cannabis policy and clinical practice by limiting research and insurance coverage. Clinicians face ongoing…
Clinical Implications of Real-World Evidence from the CARE Study [Response to Letter]
Clinical implications real world evidence from the CARE study provide valuable insights into medical cannabis outcomes. This research bridges gaps left by controlled trials by capturing diverse patient experiences. Understanding this evidence helps…
Bridging the Regulatory Chasm in Investigator‐Initiated Cannabis Research
Investigator initiated cannabis research barriers limit clinical studies and evidence-based medicine. Regulatory challenges impede rigorous cannabis research needed for informed decisions. Understanding these barriers is key to advancing cannabis…
New Washington State University Study on Smoking Cannabis: Clinical Review
The smoking cannabis study Washington State provides important clinical insights from 2026 research. This study highlights key considerations for cannabis use and patient care. Understanding these findings helps inform evidence-based clinical practice.